Nanjing Leads Biolabs Co., Ltd.
南京维立志博生物科技股份有限公司
(A joint stock company established in the People's Republic of China with limited liability)
(Stock Code: 9887)

(1) RESIGNATION OF NON-EXECUTIVE DIRECTOR; (2) PROPOSED APPOINTMENT OF NON-EXECUTIVE DIRECTOR AND (3) CHANGE IN COMPOSITION OF THE NOMINATION COMMITTEE

The board (the "**Board**") of directors (the "**Directors**", each a "**Director**") of Nanjing Leads Biolabs Co., Ltd. (南京维立志博生物科技股份有限公司) (the "**Company**", together with its subsidiaries, the "**Group**") announces the following changes to the Board:

RESIGNATION OF NON-EXECUTIVE DIRECTOR

Dr. Ni Jia (倪佳) ("**Dr. Ni**") has tendered his resignation as a non-executive Director (the "**Non-Executive Director**") of the Company, with effect from March 27, 2026.

Dr. Ni has decided to step down from his current business engagements, including those with his former employer, Shanghai Zhengxingu Investment Management Co., Ltd. (上海正心谷投資管理有限公司), and with the Company, in order to devote more time to his other future business commitments.

Dr. Ni has confirmed that he has no disagreement with the Board and there is no matter in relation to his resignation that needs to be brought to the attention of The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and the shareholders of the Company (the "**Shareholders**").

The Board would like to express its sincere gratitude to Dr. Ni for his valuable contribution to the Company during his tenure of service. Dr. Ni would also like to express his appreciation to the Company and the Board for their support during his tenure.

PROPOSED APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The Board is pleased to announce that, after taking into consideration the recommendation from the nomination committee of the Board, the Board resolved to nominate Dr. Wu Fenglan (吳鳳嵐) ("**Dr. Wu**") as a non-executive Director of the Company. The proposed appointment of Dr. Wu is subject to the approval by the Shareholders at the annual general meeting of the Company (the "**AGM**") by way of ordinary resolution.

The biographical details of Dr. Wu are set out below:

Dr. Wu, aged 42, has over 15 years of experience in the biopharmaceutical and healthcare industry. From February 2009 to October 2015, she served as a scientist at the R&D Center of GlaxoSmithKline plc. From November 2015 to July 2018, she served as a project leader and head of *in vivo* pharmacology at Zai Lab Limited, a company listed on the Stock Exchange (9688.HK). From January 2019 to July 2020, she served as a vice president at China Renaissance Holdings Limited (華興資本控股有限公司), focusing on the healthcare and biotechnology sectors. From July 2020 to January 2025, she served as the co-founder and chief executive officer of Gritgen Therapeutics Limited (華毅樂健生物科技有限公司), where she was responsible for corporate strategy, operations and fundraising. Dr. Wu joined Shanghai Zhengxingu Investment Management Co., Ltd. (上海正心谷投資管理有限公司), a private equity firm, in October 2025 and served as a managing director focusing on investment in the innovative drug sector.

Dr. Wu obtained a bachelor's degree in biopharmaceutical sciences from Tongji Medical College of Huazhong University of Science and Technology (華中科技大學同濟醫學院) in the PRC in 2006. She also obtained a master's degree in developmental biology and a doctoral degree in pharmaceutical sciences from Shanghai Jiao Tong University (上海交通大學) in the PRC in 2009 and 2020, respectively.

As of the date of this announcement, save as disclosed above, Dr. Wu had confirmed that: (i) she did not have any relationship with any other Directors, senior management, substantial or controlling Shareholders, or single largest group of Shareholders of the Company (as respectively defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**")); (ii) she did not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (iii) she did not hold any other positions within the Group; and (iv) she did not hold any directorships in any other public companies, the securities of which are listed on any securities market in Hong Kong or overseas in the last three years.

Save as disclosed above, to the best knowledge, information and belief of the Directors having made all reasonable enquiries, there is no other information relating to the proposed appointment of Dr. Wu that is required to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to (v) of the Listing Rules and there are no other matters in relation to her appointment that need to be brought to the attention of the Shareholders.

Subject to the approval of the appointment of Dr. Wu at the AGM, the Company will enter into a service contract with Dr. Wu for a term commencing from the date of the approval of the appointment of Dr. Wu at the AGM and ending on the expiry of the term of the first session of the Board, provided that her term of office will not exceed three years, and Dr. Wu is eligible for re-election at the general meeting upon the expiry of her term of office in accordance with the articles of association of the Company. Following the effectiveness of her appointment as the Non-Executive Director and pursuant to the proposed service contract, Dr. Wu will not receive Director's emolument for her position as the Non-Executive Director.

A circular which includes, among others, the information in relation to the proposed election of Dr. Wu as the Non-Executive Director, together with the notice of the AGM, will be despatched to the Shareholders (if necessary) and published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.leadsbiolabs.com) in due course.

CHANGE IN COMPOSITION OF THE NOMINATION COMMITTEE

The Board also announces that, with effect from March 27, 2026, Dr. Zhang Hongbing, an independent non-executive Director and a member of the Nomination Committee, has been appointed as the chairperson of the Nomination Committee. Dr. Kang Xiaoqiang has ceased to act as the chairperson of the Nomination Committee but remains as a member of the Nomination Committee. The composition of the Nomination Committee remains otherwise unchanged.

By order of the Board
Nanjing Leads Biolabs Co., Ltd.
南京維立志博生物科技股份有限公司
Dr. KANG XIAOQIANG
Chairman, Executive Director and Chief Executive Officer

Nanjing, PRC, March 27, 2026

As at the date of this announcement, the board of directors of the Company comprises: (i) Dr. Kang Xiaoqiang (Chairman of the Board), Dr. Lai Shoupeng and Mr. Zuo Honggang as executive Directors; (ii) Mr. Zhang Yincheng and Dr. Chen Renhai as non-executive Directors; and (iii) Dr. Zhang Hongbing, Mr. Du Yilong and Ms. Du Jiliu as independent non-executive Directors.